Related Experiment Video

Updated: Jun 7, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The management of hyperlipidemia: whether, rather than how

E H Ahrens

    Annals of Internal Medicine
    |July 1, 1976
    PubMed

    Insights

    The Lipid Hypothesis, suggesting lower plasma lipids reduce heart disease, needs reconsideration. Current evidence is insufficient, requiring further trials to adequately test this premise.

    Area of Science:

    • Cardiovascular Medicine
    • Lipidology
    • Clinical Trials

    Background:

    • The Lipid Hypothesis posits that reducing plasma lipids lowers coronary heart disease (CHD) events.
    • Recent large-scale drug trials prompt a re-evaluation of this established premise.

    Purpose of the Study:

    • To review existing evidence testing the Lipid Hypothesis through dietary and drug interventions.
    • To assess the adequacy of current data supporting the Lipid Hypothesis.

    Main Methods:

    • Systematic review of published evidence from large-scale, double-blind drug trials.
    • Analysis of data from dietary and drug intervention studies.

    Main Results:

    • The current body of evidence is insufficient to adequately test the Lipid Hypothesis.
    • Existing trials have not definitively proven the link between lipid reduction and CHD event reduction.

    Conclusions:

    • The Lipid Hypothesis requires further rigorous testing.
    • A phased program is proposed to prepare for a definitive future trial, focusing on patient adherence and regimen safety.

    More Related Videos

    Assessing Whole-Body Lipid-Handling Capacity in Mice07:57

    Assessing Whole-Body Lipid-Handling Capacity in Mice

    Published on: November 24, 2020

    Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia11:06

    Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

    Published on: April 7, 2023

    Related Concept Videos

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

    Lipid-Lowering Drugs: Statins and Miscellaneous Agents

    Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
    Cholesterol: Significance and Regulation01:29

    Cholesterol: Significance and Regulation

    Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
    Considering cholesterol and...
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...